Latest news with #PsychedelicScience2025
USA Today
15 hours ago
- Sport
- USA Today
Former Kansas City Chiefs rival discusses support for alternative therapy
Former Kansas City Chiefs rival discusses support for alternative therapy This week, Chiefs Wire's Ed Easton Jr. spoke to Jordan Poyer, a former All-Pro and Pro Bowl safety who played twelve seasons in the NFL for the Philadelphia Eagles, Cleveland Browns, Buffalo Bills, and Miami Dolphins. The conversation explored how psychedelic therapy is helping him heal from alcohol abuse in his family. On Wednesday, June 18, at Psychedelic Science 2025—the world's largest psychedelic conference, Poyer will be joined by fellow NFL standouts Robert Gallery and Jon Feliciano, who will headline a keynote conversation titled Unseen Work: Healing Behind the Highlights. "I grew up in a small town in Astoria, Oregon. I had a white mother, I had a Polynesian stepfather, who came into my life when I was two, and I never met my birth father, who is African American. I grew up in a predominantly all-white school, with maybe two or three African Americans at the school. I look back, and even at a young age, I had questions about the reality of the world that I was living in." Poyer said, "I was pretty sheltered in high school; parents didn't let me go out much, so I got to college, and that's when a lot of my drinking problems started happening. I just met friends who I'm still friends with, but we're just doing the wrong sh**, and my mother is a recovering alcoholic, my father, who is an alcoholic, and my real father, he's been in and out of prison his whole life for alcohol. So it was kind of an excuse for me always to drink; whether I played well or played badly, we drank. That flowed with me, and I played 12 years in the NFL." Poyer became an impact defensive player with the Buffalo Bills after signing in 2017. He earned All-Pro and Pro Bowl honors. He was part of many battles against the Kansas City Chiefs for the AFC crown. "I met my wife probably in my fourth year in the league. And it was at this time that I got injured, the first time I got put out for the season. Not sure where my career was going. I signed with Buffalo in 2017 when my career took off. But at the same time, I was very lost in my own identity, not knowing who I was outside of the football field, and that started to spiral out of control. I started receiving accolades, "said Poyer," and I didn't know how to handle it. My wife was pregnant, and we had just had a baby. So I used alcohol as a crutch and went down many, many holes of darkness with alcohol to the point that I was losing my wife and my daughter, and I finally decided to make a decision and go to AA (Alcoholics Anonymous). It was during the year of COVID-19 that I got sober and started going to AA. I started seeing and hearing cool stories, but I continued to fuel my curiosity; there's something deeper here. It was two and a half years after I was sober from alcohol." New Pittsburgh Steelers quarterback Aaron Rodgers went viral during his 2023 keynote about his thoughts on Ayahuasca, which heavily influenced Poyer's journey. "I heard Aaron Rodgers on a podcast talking about his Ayahuasca experience. This was again when there was so much separation in the world. They were trying to divide white people from black people; the politics were red and blue. Whatever narrative they were trying to divide us with, I never understood, and I wanted to understand what's going on in this world," said Poyer, "The story that Aaron was talking about on his Netflix show, many people wrote him off as crazy. A lot of people wrote him off as whatever. It resonated with me, and I wanted to dive deeper into what he was talking about. So, I went on my first plant medicine journey in early 2023, down to Costa Rica, which changed my life. It changed my perspective on everything. Give me more clarity on who I am, how I need to move, and why I'm here. Since then, I've gone to the Amazon. I'm going back in July, bringing my mother with me. My mother's been in the plant medicine world with me now. My brother is doing the same." Poyer was adamant about spreading the word on the positive effects of psychedelics and the usage not being illegal in the NFL. He played last season with the Miami Dolphins, finishing with 98 total tackles (51 solo) and three passes defensed for the year. "Well, it's not getting negative tests, on drug tests, and so there's really nothing that they can do about it or say about it. I was pretty open in my last couple of years about my idea of at least raising awareness around psychedelics because I can't unsee what I've seen. I can't unfeel what I felt, to the point where I couldn't pretend like nothing's going on in the world", said Poyer, "This is a responsibility of mine, to have these conversations and to use the platform that I've been able to cultivate through football, through where I thought that was my identity, The the ego part about me, and use that platform to help now raise the collective awareness. The real game is out in the world. When you take what you've learned and integrate what you can know into every situation, breath, and step of your life. I don't think the NFL world has enough or even wants to have enough information to where they would see it in some way, I'm sure, for younger players. But towards the end of my career, I stopped giving a f***. This sh** bigger than football, that's how I feel."
USA Today
2 days ago
- Health
- USA Today
Former Kansas City Chiefs Super Bowl opponent opens up about healing from personal trauma
This week, Chiefs Wire's Ed Easton Jr. spoke to Jon Feliciano, a recently retired offensive guard who played ten seasons in the NFL for the Oakland Raiders, Buffalo Bills, New York Giants, and San Francisco 49ers. The conversation explored how psychedelic therapy is helping him heal from PTSD, depression, and family issues. On Wednesday, June 18, at Psychedelic Science 2025—the world's largest psychedelic conference, Feliciano will be joined by fellow NFL standouts Jordan Poyer and Robert Gallery, who will headline a keynote conversation titled Unseen Work: Healing Behind the Highlights. "I grew up in a physically and mentally abusive household, and my whole life, I was just focused on making it to the NFL. Make it to the NFL, and my life would be great. Things would be fine. You make it to the NFL and realize things will only get worse now that you have money. Now, everyone's trying to dig in your pockets. The family aspect gets worse," said Feliciano, "My mother's calling me, threatening me to go to ESPN and say, 'I'm on drugs' or do stuff like that. Then I ended up losing my best friend, my second year in the league, who was like my brother, who knew everything about my life, and the one person I could always lean on." The veteran offensive lineman was feeling the stress and strain of family problems while playing in the NFL and was looking for ways to cope. "Up to that point, I didn't smoke, I didn't drink, I didn't do anything. When he passed away, I got into a real bad phase with alcohol and marijuana; I was having suicidal thoughts, just became a shell of myself," said Feliciano, "It wasn't until I watched the Joe Rogan podcast. Rick Doblin (Founder of the Multidisciplinary Association for Psychedelic Studies) was on it, and it opened my mind to other methods of healing. So, I started micro-dosing mushrooms. And then the big thing for me was DMT (Dimethyltryptamine), sitting in my room with the thought, 'Why do I feel this way?' How can I be better for my wife and my daughter at the time? That was my introduction, and I started doing DMT probably two or three times a year. And for me, DMT has been my lifesaver." On February 20, 2025, Feliciano announced his retirement from the NFL. He notably recalled his experience playing against the Chiefs in Super Bowl LVIII as a member of the 49ers. "The Super Bowl, honestly, if it weren't my ninth year in the league when I went to Super Bowl if it was earlier on in my career, I believe it would have been a lot mentally. Still, I was in a mindset where I could enjoy every minute," said Feliciano. "People always ask me, like, leading up to it, did it feel different? I was like, No, the only time it felt different than a regular game was standing on the sideline right before the game started when, you know, they had, like, I think it was like Post Malone and someone else singing and, staring across the Chiefs again, me, and Jordan (Poyer) had a long history with the Chiefs, was standing across from them again. The only thing that was, the only time it felt different, was just right before the ball was kicked off." Feliciano revealed the atmosphere in the locker rooms regarding conversations on the use of psychedelics. "There wasn't a conversation you could have in the locker room then. I brought it up to some guys, and everyone looked at me as if I were crazy. There was one other Buffalo (Bills) guy with whom I had gotten to do DMT with me. We ended up doing it every year before training camp, just to set our mind right." said Feliciano, "But the stigma of psychedelics, that's something that you didn't want to have on you being in the NFL, in the locker room, especially if the trainers here, or gets back to upstairs, people, they're gonna, think you're a drug addict or something. So you kept that on the down low. I will say that over the last couple of years, I feel like that has changed, whether it's because of the Aaron Rodgers (Netflix) documentary or it might have just been because I was in San Francisco."
Yahoo
2 days ago
- Health
- Yahoo
Former Kansas City Chiefs Super Bowl opponent opens up about healing from personal trauma
This week, Chiefs Wire's Ed Easton Jr. spoke to Jon Feliciano, a recently retired offensive guard who played ten seasons in the NFL for the Oakland Raiders, Buffalo Bills, New York Giants, and San Francisco 49ers. The conversation explored how psychedelic therapy is helping him heal from PTSD, depression, and family issues. On Wednesday, June 18, at Psychedelic Science 2025—the world's largest psychedelic conference, Feliciano will be joined by fellow NFL standouts Jordan Poyer and Robert Gallery, who will headline a keynote conversation titled Unseen Work: Healing Behind the Highlights. Advertisement "I grew up in a physically and mentally abusive household, and my whole life, I was just focused on making it to the NFL. Make it to the NFL, and my life would be great. Things would be fine. You make it to the NFL and realize things will only get worse now that you have money. Now, everyone's trying to dig in your pockets. The family aspect gets worse," said Feliciano, "My mother's calling me, threatening me to go to ESPN and say, 'I'm on drugs' or do stuff like that. Then I ended up losing my best friend, my second year in the league, who was like my brother, who knew everything about my life, and the one person I could always lean on." The veteran offensive lineman was feeling the stress and strain of family problems while playing in the NFL and was looking for ways to cope. "Up to that point, I didn't smoke, I didn't drink, I didn't do anything. When he passed away, I got into a real bad phase with alcohol and marijuana; I was having suicidal thoughts, just became a shell of myself," said Feliciano, "It wasn't until I watched the Joe Rogan podcast. Rick Doblin (Founder of the Multidisciplinary Association for Psychedelic Studies) was on it, and it opened my mind to other methods of healing. So, I started micro-dosing mushrooms. And then the big thing for me was DMT (Dimethyltryptamine), sitting in my room with the thought, 'Why do I feel this way?' How can I be better for my wife and my daughter at the time? That was my introduction, and I started doing DMT probably two or three times a year. And for me, DMT has been my lifesaver." On February 20, 2025, Feliciano announced his retirement from the NFL. He notably recalled his experience playing against the Chiefs in Super Bowl LVIII as a member of the 49ers. Advertisement "The Super Bowl, honestly, if it weren't my ninth year in the league when I went to Super Bowl if it was earlier on in my career, I believe it would have been a lot mentally. Still, I was in a mindset where I could enjoy every minute," said Feliciano. "People always ask me, like, leading up to it, did it feel different? I was like, No, the only time it felt different than a regular game was standing on the sideline right before the game started when, you know, they had, like, I think it was like Post Malone and someone else singing and, staring across the Chiefs again, me, and Jordan (Poyer) had a long history with the Chiefs, was standing across from them again. The only thing that was, the only time it felt different, was just right before the ball was kicked off." Feliciano revealed the atmosphere in the locker rooms regarding conversations on the use of psychedelics. "There wasn't a conversation you could have in the locker room then. I brought it up to some guys, and everyone looked at me as if I were crazy. There was one other Buffalo (Bills) guy with whom I had gotten to do DMT with me. We ended up doing it every year before training camp, just to set our mind right." said Feliciano, "But the stigma of psychedelics, that's something that you didn't want to have on you being in the NFL, in the locker room, especially if the trainers here, or gets back to upstairs, people, they're gonna, think you're a drug addict or something. So you kept that on the down low. I will say that over the last couple of years, I feel like that has changed, whether it's because of the Aaron Rodgers (Netflix) documentary or it might have just been because I was in San Francisco." Psychedelic Science 2025 —the world's largest psychedelic conference, produced by MAPS, is taking place June 16–20 in Denver, Colorado. This article originally appeared on Chiefs Wire: Ex-Chiefs Super Bowl opponent Jon Feliciano on healing from trauma
Yahoo
2 days ago
- Health
- Yahoo
Plant Medicine Track at Psychedelic Science 2025 Spotlights Ancestral Wisdom, Indigenous Sovereignty, and Being in Right Relationship
• From Peyote conservation to Religious Freedom, the Plant Medicine Track honors ancestral traditions, uplifts Indigenous leadership, and promotes ethical and reciprocal relationships with the stewards of these sacred medicines. • Featuring voices from the Amazon, Wirikuta, Sierra Mazateca (Oaxaca), and tribal nations within the United States, speakers include Sandor Iron Rope, Osiris Garcia Cerqueda, Daiara Tukano, Christine McCleave, Chief Nixiwaka Yawanawá, and Raine Piyãko. • Sessions explore ancestral healing practices, biocultural conservation, Indigenous sovereignty, sacred plant protection, and the ethics of Psychedelic Science and policy reform. DENVER, June 12, 2025 (GLOBE NEWSWIRE) -- With growing recognition of psychedelics and plant medicines in therapeutic and scientific settings, it is a critical time to uplift and acknowledge the Indigenous wisdom and practices that preceded and guide today's progress. Psychedelic Science 2025 (PS2025) honors these roots with a dedicated Plant Medicine Track that highlights spiritual, cultural, and ecological dimensions of Indigenous practices with sacred plants. Hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), PS2025 takes place June 16–20 at the Colorado Convention Center in Denver. With more than 500 speakers across five days, the gathering convenes a global community of scientists, healers, advocates, leaders, and Indigenous knowledge-keepers. Among its many offerings, the Plant Medicine Track stands out as an immersive and robust forum covering ancestral traditions, religious freedom, Indigenous sovereignty, and biocultural healing practices, and their intersection with the psychedelic movement. The Plant Medicine Track weaves together a rich spectrum of themes, from preserving endangered sacred plants and habitats, to whether we can responsibly integrate Indigenous knowledge in contemporary therapy and science, to utilizing modern psychedelic therapy practices to support the healing of tribal, Native, and other Indigenous communities across the world. Key focus areas include: Biocultural Protection – Safeguarding sacred plants and their ecosystems (for example, the peyote cactus in Wirikuta and South Texas (the Chihuahuan Desert) alongside the cultures that revere them, blending conservation with cultural rights. Indigenous Leadership – Highlighting Indigenous voices and sovereignty in the psychedelic ecosystem, including thoughtful perspectives from elders and youth alike on how to respect, share, and regulate plant medicines in today's globalized world. Grassroots Healing – Spotlighting community-driven healing initiatives that merge ancestral practices with modern approaches to address challenges like addiction, trauma, and social inequality. Legal & Ethical Frameworks – Exploring the evolving legal landscape and ethical guidelines for sacred medicine use – from religious freedom and policy reform to protocols for respectful engagement and benefit-sharing with Indigenous communities. 'One of the most important themes of Psychedelic Science 2025 is the relationship between the psychedelic movement and the many Indigenous communities that preceded it, participate in it, and are impacted by it. MAPS is proud to work alongside, learn from, and be in relationship with tribal, Native American/Alaska Native, and Indigenous people from across the country and the world. We honor the spectrum of identity represented by land-based practices, celebrate efforts to reclaim or reconnect to them, and acknowledge the complexity that comes alongside navigating indigeneity and territoriality in a globalized world. The Plant Medicine Track is one way we highlight these topics and ensure that the contemporary psychedelic movement remains grounded in respect, reciprocity, and reverence for its roots.' — Ismali Lourido Ali, J.D., Interim Co-Executive Director, MAPS From legacy Indigenous healers and dedicated conservationists to activists and cutting-edge scientists, PS2025's Plant Medicine Track focuses on the deep connections between culture, ecology, and healing that drive the psychedelic field – and the responsibility we all have to our larger community. Thanks to US-based nonprofit organizations, including the Indigenous Medicine Conservation Fund (IMC Fund), which works to directly lift up voices from Indigenous communities around the world, and the Chacruna Institute, which maintains an incredible commitment to including Indigenous voices in the psychedelic ecosystem. It behooves all of us to educate ourselves on these delicate subjects, and MAPS is proud to be highlighting the vision and the possibility that this psychedelic effort can continue without doing harm. Indigenous-Led Sessions – Talks and panels on multiple stages that are guided by Indigenous elders and knowledge-keepers from across the Americas, Africa, and beyond, sharing perspectives rarely heard outside their communities. Cross-Cultural Exchange – Dialogues bridging traditional wisdom with modern science, and connecting different generations and cultures to foster mutual learning about healing, conservation, and community well-being. Ethical & Sustainable Practices – Forward-looking discussions on tensions that come with integrating psychedelics into society, including the establishment of entheogenic churches, international policy on Indigenous rights, and best practices for reciprocity, sustainability, and ecological responsibility. Alliance-Building – Networking opportunities to connect with Indigenous leaders, researchers, and fellow advocates, and opportunities to forge partnerships and alliances to support biocultural conservation and cross-cultural initiatives around the world. Featured Sessions Setting the Principles for Cultural Appreciation and Respectful RelationshipTo kick off the Plant Medicine Track, this panel features an international delegation of Indigenous medicine practitioners, Raine Piyåko (Vice President, Yorenka Tasorentsi Institute), Steven Benally (Founding Board Member, Indigenous Peyote Conservation Initiative), Georges Gassita (Secretary General of the Board of Directors, Blessings of the Forest Gabon), and Madsa' Juårez (as moderator; Co-Executive Director, Indigenous Medicine Conservation Fund) will explore respectful interaction with medicines and the people that steward them, opening the track for the possibility of Cultural Appreciation and proper knowledge sharing. Sacred or Stolen? The Fine Line Between Cultural Appreciation and Appropriation in Psychedelic Healing As plant medicine gains mainstream attention, there's growing concern over who controls the narrative and who benefits. Are Western psychedelic practitioners honoring Indigenous traditions or erasing them? This conversation with Lígia Duque Platero, Ph.D. (Education Program Associate, Chacruna Institute), Osiris García Cerqueda, Ph.D. (Indigenous Mazatec historian and sociologist), and Nico Gusac (as moderator) explores cultural appropriation, reciprocity, and ethical ways to engage with plant medicine traditions without perpetuating harm. Declaration from the Indigenous Medicine Conservation Fund to Psychedelic ScienceOn the Keynote stage, Christine McCleave (CEO, National Native American Boarding School Healing Coalition) and Daiara Tukano, MA (Indigenous Rights Activist, Brazil) will read the Declaration from the IMC Fund Indigenous Delegation to PS2023 which was published after the previous conference, with new additions based on two days of discussion in the plant medicine track at PS2025. Peyote: History, Biocultural Considerations and Indigenous PerspectivesIt was only as recently as 1994 that the right of Native American Church members to practice with their sacred Peyote medicine was guaranteed by the Native American Freedom of Religion Act. Today, wild Peyote cactus populations are extremely at risk. This panel brings together Sandor Iron Rope (Board Member, Indigenous Peyote Conservation Initiative) and Lucy Benally (Board Member, Indigenous Medicine Conservation Fund), members of the Native American Church, to discuss advances and possibilities for the future of the Peyote cactus and the people who utilize it as their way of life. Moderated by Miriam Volat, MA (Co-Director, Riverstyx Foundation). Ayahuasca: Biocultural Overview and Indigenous ConsiderationsThe globalization of ayahuasca over the past several decades has had multifaceted impacts on Indigenous communities across the Amazon basin. This panel brings together Indigenous leaders from Peru, Colombia, and Brazil who are actively working for the conservation of their cultural heritages and toward the proper use of ayahuasca as a medicine. Miguel Evanjuanoy Chindoy (Co-Director, Indigenous Medicine Conservation Fund), Chief Nixiwaká Biraci Yawanawá (Spiritual and political leader, Yawanawá people, Brazilian Amazon), Chief Yama Nomanawa (Leader, Noke Koi villages, Brazil), and Daiara Tukano, MA (as moderator) will discuss pertinent themes from on-the-ground experiences at the intersection of preserved traditional practices and the Western market, including collective efforts like forming an ancestral doctor's union, leveraging Western interest in ayahuasca to benefit Indigenous communities, and advancing territorial rights in the face of foreign industrial interests. Churches and the New Psychedelic Emergence: Ancestral Medicines and the Growing MovementThe Religious Freedom Restoration Act provides a legal mechanism for church groups in the United States to use otherwise-scheduled medicines and substances as part of their so-called religious practices. But what are Indigenous perspectives on this movement? Walter López (President, ASOMASHK), Sandor Iron Rope (Board Member, Indigenous Peyote Conservation Initiative), Sean McAlliser (Attorney), and Miriam Volat, MA (as moderator) will describe the international frameworks that exist for the protection of Indigenous knowledge and resources, examine concerns around the legalization of psychedelic churches from the viewpoint of Indigenous leaders, and offer considerations for the way forward. Romantic Delusions: What We're Not Talking About in Plant Medicine Circles?Cassandra Muileboom will moderate a discussion between Bia Labate, Ph.D. and Nico Gusac of the Chacruna Institute that confronts the seductive narratives surrounding plant medicines—the romanticism, mystification, and spiritual consumerism that often obscure uncomfortable truths. It critically examines how plant medicine culture frequently glosses over issues of risk, trauma, mental health crises, and abuse. The conversation also explores how the idolization of 'healers,' particularly within Indigenous and neo-shamanic contexts, fosters environments ripe for power abuse and spiritual bypassing. It further tackles the problematic idealization of Indigenous peoples as pure, enlightened stewards of the Earth—an image that erases complexity, material struggle, and political demands. International Legal Frameworks, Indigenous Medicine, and the Psychedelic MovementDaiara Tukano, MA, Patricia Tóbon Yagarí (Indigenous lawyer, Colombia), Christine McCleave and Madsa' Juárez (as moderator) map out the landscape of global policies that intersect with Indigenous medicine traditions. From United Nations agreements on biodiversity and traditional knowledge to evolving drug laws in countries like the United States, Mexico, and Gabon, this session highlights how well (or poorly) current frameworks safeguard Indigenous communities and their sacred plants. It also challenges psychedelic advocates to go beyond legal minimums by adopting higher standards of respect, benefit-sharing, and ecological responsibility, sharing real examples of both progress and ongoing challenges at this critical intersection. Indigenous-Led Biocultural Conservation Success Stories with Ayahuasca, Iboga, and PeyoteActivism for policy change can be a hugely unifying force. MAPS Interim Co-Executive Director Ismail Lourido Ali will moderate a Keynote stage panel of high-profile lawyers, Patricia Tobón, Georges Gassita, and James Botsford, all of who have worked in Indigenous movements for decades, to discuss how protections for Indigenous rights — specifically related to Indigenous sacred medicine use — directly benefits communities and conservation efforts on the ground. Chacruna Sidebar Conversations: Sacred Plants, Decolonial DialoguesThe Chacruna Institute is offering dedicated conversations within the hallway of the convention center, with the intention to foster deep connection, collective wisdom, and community empowerment within the psychedelic field. These gatherings will include conversations such as 'From Reciprocity to Sovereignty: Sacred Plants Conservation and Community,' with Osiris García Cerqueda, Ph.D., Lígia Duque Platero, Ph.D., Karina Alvarez, and Marta Camagna; 'Healing with Plants: An Intimate Conversation with Maestro José López and Anne-Laure Vincke; and more. Other featured voices in the Plant Medicine Track include Stanley Krippner, Ph.D. (pioneering psychologist and shamanism researcher), David Bronner (Cosmic Engagement Officer, Dr. Bronner's), and many more – each adding a unique perspective from traditional knowledge to modern science. Together, these speakers embody the inclusive spirit of Psychedelic Science 2025, where ancient wisdom and contemporary research unite to shape the future of healing. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come basis. About Psychedelic SciencePsychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for producing iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACTmedia@
Yahoo
3 days ago
- Health
- Yahoo
Psychedelic Science 2025 Unveils Science, Studies & Trials Tracks Showcasing Next Generation in Brain Imaging, Clinical Trials, and Neuroplasticity
• Sessions cover the latest updates in psychedelic neuroscience, from psilocybin's effects on brain connectivity to trial design, clinical outcomes for PTSD, depression, addiction, and OCD, and the future of drug development through translational models and AI innovations • Speakers include globally renowned experts like Gabrielle Agin-Liebes, Ph.D., Michael Bogenschutz, M.D., Robin Carhart-Harris, Ph.D., Alan K. Davis, Ph.D., Gül Dölen, M.D., Ph.D., Ben Kelmendi, M.D., Franklin King, M.D., Amy Lehrner, Ph.D., Leslie Morland, Psy.D., David Nutt, Ph.D., Stephen Ross, M.D., Emmanuelle Schindler, M.D., Ph.D., and Nolan Williams, M.D. • Representing institutions include Columbia, CU Denver, Imperial College London, Johns Hopkins, LSU, Massachusetts General Hospital, NYU, Ohio State, Stanford, UC Berkeley, UCSD, UCSF, University of Alabama, University of New Mexico, University of Washington, and numerous VA centers DENVER, June 11, 2025 (GLOBE NEWSWIRE) -- Psychedelic Science 2025 (PS2025), the world's leading conference on psychedelic research, medicine, policy, and culture hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), announced its Science, Studies, and Trials tracks—three of the conference's most anticipated and data-rich offerings. Taking place June 16–20, 2025, at the Colorado Convention Center in Denver, PS2025's research tracks will convene top clinical investigators, neuroscientists, biotech pioneers, and social scientists to present a comprehensive and cross-disciplinary view of this transformative field of study. At a time when the global mental health crisis continues to grow, PS2025 showcases therapeutic research using psychedelic compounds such as psilocybin, MDMA, LSD, DMT, 5-MeO-DMT, and ketamine, which are being investigated as treatments for serious mental illnesses such as addiction, depression, PTSD, obsessive-compulsive disorder, as well as neurological conditions such as pain, Alzheimer's, Lyme Disease, and Parkinson's. Beyond clinical trials, PS2025 also offers the latest in psychedelic neuroscience, examining data from studies using new neuroimaging, cellular, and molecular research tools that deepen the understanding of the biological mechanisms underlying their remarkable effects. Social science research is also included that examines the usage, attitudes, and experiences of trial participants, psychedelic consumers, and the general public, providing important context for societal views about this rapidly growing field. 'With the science and understanding of psychedelic substances expanding exponentially in recent years, we're honored to welcome some of the world's top academic researchers to PS2025 so they can share this new knowledge with attendees from around the globe.'— Philippe Lucas, Ph.D., Director, Research & Safe Access, MAPS The Science, Studies, and Trials tracks will feature both senior research leaders as well as emerging voices from public and private universities throughout North America, as well as international institutions in the UK, Europe, and Latin America. This highly anticipated convergence allows scientists to engage deeply about hot topics, including durability of efficacy, safety and risk, placebo dynamics, the role of psychotherapy, transdiagnostic effects, precision psychiatry, biological mechanisms, novel compounds, and the role of government grants and private capital in innovation. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come basis. Featured sessions in the Science, Studies, and Trials tracks include:20 Years of Human Neuroscience Research with PsychedelicsDavid Nutt, Ph.D., reflects on two decades of pioneering work using brain imaging and neuropharmacology to explore consciousness, depression, and psychedelic mechanisms of action. Psychedelic Frontiers at the National Institutes of Health: NIH-funded Studies, Research Opportunities, and PrioritiesJoin a conversation moderated by Stacy Fischer, M.D., featuring Michael Bogenschutz, M.D., and Patrick Finan, Ph.D., as they unpack the latest NIH-funded studies, explore future research opportunities, and discuss the evolving priorities shaping this rapidly growing field of psychedelic-assisted therapy. Frontiers in Psilocybin Research for OCD: Neural Mechanisms, Treatment Response, and Clinical ImplicationsIn a session moderated by Jamila Hokanson, M.D., Ben Kelmendi, M.D., and Terence Ching, Ph.D., explore cutting-edge research on psilocybin's neural effects, clinical outcomes, and its potential as a treatment for OCD. Studies of Psychedelic-Assisted Therapy for Addiction DisordersJoin a conversation with Matthew Johnson, Ph.D., and Rayyan Zafar, Ph.D., moderated by Peter Hendricks, Ph.D., for a discussion on the latest research into the use of psychedelics as tools to treat addiction. This session will explore emerging evidence, clinical insights, and the challenges and promises of integrating psychedelic-assisted therapy into addiction treatment frameworks. Psychedelic Therapy for Military Veterans: A New Paradigm of Healing the Wounds of WarModerated by Chris Stauffer, M.D., and featuring Allie Kaigle, PharmD, BCPP, Amy Lehrner, Ph.D., and Leslie Morland, Psy.D., this session examines how psychedelic-assisted therapies are reshaping the landscape of care for Veterans grappling with PTSD, depression, and moral injury. By combining cutting-edge research with lived experience, these experts reveal how these innovative therapies can unlock hope, resilience, and lasting healing for those who have Outcomes from a Trial of Psilocybin-Assisted Therapy for Major Depressive DisorderIn this presentation, Alan K. Davis, Ph.D., shares groundbreaking findings from a long-term follow-up study examining the sustained effects of psilocybin-assisted therapy for individuals with major depressive disorder and what these results mean for the future of psychedelic treatments in mental health care. Ayahuasca: Bridging Molecular and Clinical Insights – A Multidisciplinary PanelDráulio Araújo, Ph.D., moderates a conversation with Fernanda Palhano-Fontes, Ph.D., Marcelo Falchi Parra Carvalho Silva, M.D., and Marcelo Leite, Ph.D., on the multifaceted world of ayahuasca through a unique convergence of molecular research, clinical practice, and traditional wisdom. The conversation offers insights into ayahuasca's molecular mechanisms and its applications in healing trauma and supporting personal growth. Developing Ibogaine for Opioid Use Disorder: Bridging Science, Public Benefit, and Sacred RootsSusan Ousterman moderates a conversation with Jeremy Weate, Ph.D., Ryan Rich, and Peter Hendricks, Ph.D., on the journey of ibogaine from traditional medicine to modern addiction therapy. Together, they'll explore clinical advancements, regulatory challenges, and how to ethically integrate indigenous knowledge and practices to address the opioid epidemic. Improving Standardization and Reducing Bias in Psychedelic Drug Development Trials Using an AI-Enabled PlatformJennifer Tippett, Psy.D., and Danielle Schlosser, Ph.D., discuss how artificial intelligence can transform psychedelic research by improving standardization, reducing bias, and enhancing data quality in clinical trials. Discover how this innovative approach is shaping the next generation of rigorous, ethical, and effective psychedelic drug development. The Potential for Psychedelic-Assisted Therapy in Conflict-Affected Populations: Ukraine and the BalkansModerated by Tadeusz Hawrot and featuring Oksana Gryshchenko, Elise Wilson, Zina Besirevic, Ph.D., and Galyna Pidpruzhnykova, Ph.D., this panel explores how psychedelic-assisted therapies might offer pathways to healing for individuals and communities affected by war and Differences in Therapeutic Outcomes Between Synthetic Psilocybin and Whole Psilocybe Mushrooms: A Qualitative StudyJoin Pamela Kryskow, M.D., and Joseph La Torre, Ph.D., as they present their qualitative study exploring the participants' lived experiences and perceptions, offering a deeper understanding of how these distinct forms of psilocybin influence healing, integration, and personal transformation. The Unique Challenges and Potential for Studying Psychedelic-Assisted Therapy for Palestinians and Jews in IsraelModerated by Keren Tzarfaty, Ph.D., MFT, and featuring Adar Avnon, Sidi Ronen, Ph.D., and Clinical Psychologist Wasim Biroumi, this session dives into the promise and complexities of researching psychedelic-assisted therapy in the unique socio-political landscape of Israel. The panel will discuss how shared trauma and cultural dynamics shape therapeutic approaches and the role psychedelics may play in fostering healing, understanding, and resilience across Outcomes from Yale's Real-World Psilocybin Trial: Connecticut-Funded Pioneering Psychedelic Therapy Program and Insights from Other State InitiativesJesse MacLachlan and Gabrielle Agin-Liebes, Ph.D., share findings from Yale's groundbreaking psilocybin trial, the first state-funded psychedelic therapy program in the U.S. This session will examine the transdiagnostic benefits observed in real-world settings and highlight key insights from Connecticut's initiative alongside other state-led programs shaping the future of psychedelic-assisted Critical Periods and Cephalopods: A Conversation with Neuroscientist Dr. Gül DölenJoin Gül Dölen, M.D., Ph.D., and Amy Emerson for a fascinating conversation that spans critical periods in brain development and the remarkable learning abilities of cephalopods. This session will illuminate the connections between these insights and the potential of psychedelics to re-open windows of plasticity in the adult brain. Listening to Lead: How a Community-Informed Psilocybin Study is Guiding New Mexico's Regulated ModelCrystal Romero, Janus Herrera, Dara Menashi, Ph.D., Larry Leeman, M.D., and Hanifa Nayo Washington (moderator) explore how New Mexico's historic Senate Bill 219 is paving the way for the nation's first state-regulated medical psilocybin program. This panel spotlights the community-informed pilot study by the Psychedelic Health Equity Initiative (PHEI), designed to center equity, accessibility, and culturally attuned care for underserved communities. Expanding the Lens: Mechanisms, Models & Modes - Transdiagnostic Potential of Psychedelic MedicinesJoin Charles Nichols, Ph.D., and Robin Carhart-Harris, Ph.D., as they unpack the unique mechanisms and models of action that position psychedelics as potential transdiagnostic treatments by addressing shared root causes across conditions. Treating Care Providers and Long COVID with Psychedelic-Assisted TherapyAnthony Back, M.D., moderates a vital discussion with Lawrence Purpura, M.D., Ph.D., Benjamin Lewis, M.D., Kush Bhatt, M.D., and Saleena Subaiya, M.D., on the emerging promise of psychedelic-assisted therapy to help those suffering from long COVID and the burnout experienced by care providers. This session will share clinical updates, innovative approaches, and new possibilities for fostering healing for those on the front lines of care. A Machine Learning Perspective on Psychedelics and PsychopathologyArthur Juliani, Ph.D., shares how artificial intelligence is revolutionizing clinical trial design, protocol optimization, and predictive modeling for psychedelic studies. From Rodents to Humans: Unlocking the Science of Psychedelic-Induced NeuroplasticityModerated by Lindsay Cameron, Ph.D., and featuring Manesh Girn, Ph.D., Max Vargas, Ph.D., and Neil Savalia, M.D./Ph.D(c), this session investigates the limitations of preclinical models in capturing the complexity of human psychedelic experiences and what these challenges mean for the future of psychedelic drug development. Psilocybin Desynchronizes the Human BrainJoin Joshua Siegel, M.D., Ph.D., as he delves into cutting-edge research exploring how psilocybin disrupts established patterns of brain connectivity – unpacking how these transient states of neural desynchronization might illuminate new pathways for therapeutic breakthroughs, and revealing the brain's remarkable flexibility and potential for healing. About Psychedelic SciencePsychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for producing iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACTmedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
